KALV (KALV)
KalVista Pharmaceuticals, Inc.
NASDAQ:KALVHealthcare · Biotechnology
+0.04%$27.00
Mkt Cap-
Float34.75M
O/S-
Inst Own-
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
Country
US
USIPO DateApr 9, 2015
Shares Outstanding-
Float34.75M
Company Overview
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need.
Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa.
The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
Leadership
Benjamin L. Palleiko
Chief Executive Officer & Director
Brian J. G. Pereira
Director and Chairman
Edward W. Unkart
Director
Laurence Reid
Director
Employees
275
Country
US
Sector
Healthcare
Website
kalvista.com
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
No price targets availableRatings Distribution
BUY11
HOLD2
SELL0
TOTAL13
Insider Trading
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Unkart Edward W | Director | Withholding/Transfer | 10.0K | -- | Jun 11, 2026 |
 Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER | Withholding/Transfer | 125.0K | -- | Jun 11, 2026 |
 Sweeny Nicole | Chief Commercial Officer | Withholding/Transfer | 68.8K | -- | Jun 11, 2026 |
 Audhya Paul K. | CHIEF MEDICAL OFFICER | Withholding/Transfer | 68.8K | -- | Jun 11, 2026 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | Withholding/Transfer | 40.0K | -- | Jun 11, 2026 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER | Withholding/Transfer | 93.8K | -- | Jun 11, 2026 |
Shareholders
--
Institutional
(2)
--
Insiderⓘ
(0)
--
5%+ Owners
(1)
--
Unattributed (incl. retail)ⓘ
Top Shareholders
| Name | Shares | % | Source |
|---|---|---|---|
Point72 Asset Management, L.P. · filed May 2026 | 2.1M | 4.2% | 13G |
Millennium Management LLC · filed May 2026 | 1.9M | 3.7% | 13G |
Frazier Life Sciences Public Fund, L.P. · joint filing· may incl. warrants· filed May 2026 | 1.2M | 2.3% | 13D |
JANUS HENDERSON GROUP PLC | 10.9K | -- | 13F |
CWM, LLC | 901 | -- | 13F |
Sources: 13F, Form 4, 13D/13G
Insiders & Institutional Holders
Insiders
- Unkart Edward WDirector
- Palleiko Benjamin LCHIEF EXECUTIVE OFFICER
- Sweeny NicoleChief Commercial Officer
- Audhya Paul K.CHIEF MEDICAL OFFICER
- Yea ChristopherCHIEF DEVELOPMENT OFFICER
- Stuart NancyDirector
- Treanor PatrickDirector
- Reid LaurenceDirector
- Arif BilalChief Operations Officer
- Fairey WilliamDirector
Top institutional holders
Key Metrics
Market Cap--
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership--
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUS
USIPO DateApr 9, 2015
Shares Outstanding-
Float34.75M
52-Week Range
$9.83$27.00
$27.00(100th percentile)
Volume
Average Daily Volume--
30d Avg
--
60d Avg
--
90d Avg
--
Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...